Trial · NCT03715153
Adverse events308
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 308
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Blood creatinine increased | Investigations | S95008 - Double-blind Period (Week 0-26) | 6 | 107 | 6 |
| other | Blood creatinine increased | Investigations | Placebo - Double-blind Period (Week 0-26) | 3 | 104 | 3 |
| other | Blood creatinine increased | Investigations | S95008/S95008 - Open-Label Extension Period (Week 26-52) | 11 | 84 | 11 |
| other | Blood creatinine increased | Investigations | Placebo/S95008 - Open-Label Extension Period (Week 26-52) | 5 | 92 | 5 |
| other | Blood uric acid increased | Investigations | S95008 - Double-blind Period (Week 0-26) | 5 | 107 | 6 |
| other | Blood uric acid increased | Investigations | Placebo - Double-blind Period (Week 0-26) | 0 | 104 | 0 |
| other | Blood uric acid increased | Investigations | S95008/S95008 - Open-Label Extension Period (Week 26-52) | 5 | 84 | 6 |
| other | Blood uric acid increased | Investigations | Placebo/S95008 - Open-Label Extension Period (Week 26-52) | 2 | 92 | 2 |
| other | Weight decreased | Investigations | S95008 - Double-blind Period (Week 0-26) | 13 | 107 | 13 |
| other | Weight decreased | Investigations | Placebo - Double-blind Period (Week 0-26) | 2 | 104 | 2 |
| other | Weight decreased | Investigations | S95008/S95008 - Open-Label Extension Period (Week 26-52) | 12 | 84 | 13 |
| other | Weight decreased | Investigations | Placebo/S95008 - Open-Label Extension Period (Week 26-52) | 10 | 92 | 10 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | S95008 - Double-blind Period (Week 0-26) | 4 | 107 | 4 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Placebo - Double-blind Period (Week 0-26) | 7 | 104 | 8 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | S95008/S95008 - Open-Label Extension Period (Week 26-52) | 6 | 84 | 7 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Placebo/S95008 - Open-Label Extension Period (Week 26-52) | 6 | 92 | 7 |
| other | Akathisia | Nervous system disorders | S95008 - Double-blind Period (Week 0-26) | 8 | 107 | 8 |
| other | Akathisia | Nervous system disorders | Placebo - Double-blind Period (Week 0-26) | 4 | 104 | 5 |
| other | Akathisia | Nervous system disorders | S95008/S95008 - Open-Label Extension Period (Week 26-52) | 7 | 84 | 7 |
| other | Akathisia | Nervous system disorders | Placebo/S95008 - Open-Label Extension Period (Week 26-52) | 4 | 92 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03715153/events